Comparison of Training, Anthropometric, Physiological and Psychological Variables of Ultra-Endurance Cyclists and Runners

AbstractWe compared training, anthropometric, physiological and psychological characteristics between 14 cyclists, participants in a 24-hour mountain bike race and 12 runners, participants in a 7-day running ultra-marathon. Methods: Questionnaires and physiological measurements. Results: The differences in ages between cyclists and runners were significant (p << 0.01). The pre-race minus post-race differences (Δ) in body mass (from 76.5 ± 13.1kg to 72.0 ± 12.0kg) and (Δ) in value of hematocrit (6.1 ± 3.5%) were significant only in runners. The post-race minus pre-race difference (Δ) in the rating of perceived exertion was significant in both groups

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)

Characterising the individual ear by the "Auditory Profile"

This paper describes a new approach to auditory diagnostics, which is one of the central themes of the EU-project HEARCOM. For this purpose we defined a so-called "Auditory Profile" that can be assessed for each individual listener using a standardized battery of audiological tests that - in addition to the pure-tone audiogram - focus on loudness perception, frequency resolution, temporal acuity, speech perception, binaural functioning, listening effort, subjective hearing abilities, and cognition. For the sake of testing time only summary tests are included from each of these areas, but the broad approach of characterizing auditory communication problems by means of standardized test is expected to have an added value above traditional testing in understanding the reasons for poor speech reception. The Auditory profile may also be relevant in the field of auditory rehabilitation and for design of acoustical environments. The results of an international 5-center study (in 4 countries and in 4 languages) will be presented and the relevance of a broad but well-standardized approach will be discussed.<br/